KCT0009058
Recruiting
未知
AI-based Novel Diabetes Classification and Prognostic Prediction in Korean cohort studies: a gateway to precision medicine in diabetes
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Endocrine, nutritional and metabolic diseases
- Sponsor
- Korea University Ansan Hospital
- Enrollment
- 250
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients diagnosed with type 2 diabetes within the last 3 years
- •Age 19 and above, under 80
Exclusion Criteria
- •Patients with type 1 diabetes
- •Those currently taking medications such as systemic steroids, obesity treatment drugs, or other medications that can affect current blood glucose levels
- •Patients deemed inappropriate for clinical research (e.g., pregnant individuals, severe systemic illnesses, mental disorders, etc.)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Clinical trial of patients with type 2 diabetes and obesity randomly allocated to be implanted with an intestinal liner device with or without standard diabetes liraglutide medical therapy or liraglutide alone.Combined Type 2 diabetes mellitus and obesity.MedDRA version: 14.1Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate controlSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]EUCTR2012-004988-42-GBSandwell and West Birmingham Hospitals NHS Trust
Unknown
Not Applicable
A Single Center Study on Comparing the Different Function of EndoAngel in Improving the Quality of ColonscopyAdenomaNCT04453956Renmin Hospital of Wuhan University1,090
Unknown
Phase 2
Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by InflammatioPatients with IgA nephropathyIgA nephropathyD41.0LBCTR2020023394ovartis Pharmaceuticals4
Active, not recruiting
Phase 1
Two-part Clinical Study to Evaluate the Safety and Benefits of NaBen® in Adolescents with SchizophreniaTreatment for Schizophrenia in AdolescentsMedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2017-001168-39-PLSyneuRx International (Taiwan) Corp126
Active, not recruiting
Phase 1
Two-part Clinical Study to Evaluate the Safety and Benefits of NaBen® in Adolescents with SchizophreniaTreatment for Schizophrenia in AdolescentsMedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2017-001168-39-GBSyneuRx International (Taiwan) Corp126